Abstract: Objective：To investigate the clinical efficacy of dose-dense chemotherapy and standard chemotherapy regimen in the treatment of advanced epithelial ovarian cancer. Methods：Select 89 patients who were diagnosed by pathology with advanced epithelial ovarian cancer in The Fifth Central Hospital of Tianjin. The patients were randomly divided into dose dense group of 45 cases and a standard regimen in 44 cases，the age，pathological type and clinical stage of the two groups patients were not statistically significant （P＞0.05）. Standard solutions group：Paclitaxel 180 mg/m2（intravenous drip for 3 h），then the use of carboplatin AUC 6（intravenous drip for 1 h，the first day），the interval of 3 weeks，a total of 6 courses. Dose dense group：Paclitaxel 80 mg/m2 1，8，15 days + carboplatin AUC 6（intravenous drip for 1 h，the first day），during the interval of 3 weeks，a total of 6 courses. The two groups were treated and followed up for 3 years，compared the two groups of patients with long-term efficacy，therapeutic effect and adverse reaction. Results：The total remission rate of dose dense group was higher than that of the standard regimen group，the difference was statistically significant（P＜0.05）. Comparison of progression free survival and 3 year survival rate，the dose dense group was significantly higher than that of standard solutions group （P＜0.01）. Although the incidence of the adverse reaction rate was also higher than that of the standard regimen group，there was statistically significant but only Ⅲ～Ⅳ anemia incidence rate difference between the two groups （P＜0.05），the rest incidences were no significant difference（P＞0.05）. Conclusions：The dose dense chemotherapy can effectively improve the 3 year survival rate of advanced epithelial ovarian cancer patients，delaying tumor recurrence.

Key words: Ovarian neoplasms, Drug therapy, combination, Paclitaxel, Carboplatin